Introduction: Abnormalities of serum testosterone level in males are observed in chronic kidney disease (CKD) patients. Erectile dysfunction, decreased libido, infertility in chronic kidney disease (CKD) patients is associated with low serum testosterone. So this study of CKD patients help early recognition of these adverse conditions associated with low serum testosterone level and thus specific actions may be taken earlier.
primary hypogonadism and disturbances of the hypothalamic-pituitary axis) are already seen when moderate reductions in the GFR arise (Richardson & Weinstein 1970) . These disorders are not normalized with initiation of maintenance dialysis treatment; instead, they often progress (de Vries et al. 1984 ). Morley et al. (2000) examined whether certain symptoms are more commonly present in males with low bioavailable testosterone (BT) levels. These were used to evaluate a questionnaire for androgen deficiency in aging males (ADAM). The validity of the ADAM questionnaire to screen for low BT was tested in 316 Canadian physicians aged 40 to 62 years. Low BT levels were present in 25% of this population. None had elevated luteinizing hormone (LH) levels. The ADAM questionnaire had 88% sensitivity and 60% specificity. When the questionnaire was administered twice 2 to 4 weeks apart to 10 men, it was determined that the coefficient of variation was 11.5%. In a second study of 34 ADAM-positive patients, 37% of those with clearly normal BT levels demonstrated some evidence of dysphoria. Finally, in 21 patients who were treated with testosterone, improvement on the ADAM questionnaire was demonstrated in 18 (P <0.05). These data support the concept of a symptom complex associated with low BT levels in aging males. In addition, the ADAM questionnaire appears to be a reasonable screening questionnaire to detect androgen deficiency in males over 40 years of age. So this study of CKD patients help early recognition of these adverse conditions associated with low serum testosterone level and thus specific actions may be taken earlier. And thus, this study has done to evaluate the serum testosterone level and the response of ADAM questionnaire in males with different stages of chronic kidney disease.
Methods:
This Cross sectional study was conducted on 178 subjects, among them different stages of CKD patients 90 and age matched healthy individuals 88 at Department of Nephrology, Dhaka Medical College Hospital, Dhaka. CKD patients of stage 3, 4, 5 (with estimated glomerular filtration rate (eGFR) 30-59 ml/min, 15-29 ml/min, <15 ml/min without dialysis), according to MDRD formula respectively, stage 5D on maintenance hemodialysis were included. Patients having critical illness, taking spironolactone, glucocorticoids, finasteride, cyclophosphamide, cyclosporin A and tacrolimus, age < 20 or >60 were excluded from this study. Every subject was provided the androgen deficiency in aging males (ADAM) questionnaire (Morley, et al. 2000) . Bangla version of ADAM questionnaire was made from Bangla Academy. This questionnaire was explained to every subject and completed confidentially. Diagnosis of CKD was confirmed by history, clinical examination, biochemical findings and imaging. All CKD patients were designated as group 'A' (total no. 90), healthy control group were grouped as group 'B' (total no. 88). Clinical and biochemical finding of the CKD patients (group A) was compared with that of the healthy control group (group B).
Data processing and data analysis:
Statistical analyses were carried out by using the Statistical Package for Social Sciences version 16.0 for Windows (SPSS Inc., Chicago, Illinois, USA). The mean values were calculated for continuous variables. The quantitative observations were indicated by frequencies and percentage shown with cross tabulation. Student t-test was used for continuous variables for two groups. For significance of difference Spearman correlation co-efficient test was done between stage of CKD and S. Testosterone of CKD patients. Pearson's correlation coefficient was used to test the relationship between two continuous variables. P values <0.05 was considered as statistically significant.
Results:
Majority 37(41.1%) patients belonged to age 41-50 years. The mean age was found 42.74±10.2 years. More than two third (66.7%) patients had normal (3.2-14.6 ng/ml) S. testosterone and their mean S. testosterone were found 4.29±1.9 ng/ml. Positive ADAM questionnaire was found 62(68.9%) patients (Table-1 ). It was observed that majority 36(40.9%) subjects belonged to age 41-50 years. The mean age was found 42.8±9.8 years. All subjects had normal (3.2-14.6 ng/ml) S. testosterone and their mean S. testosterone were found 9.15±1.2 ng/ml. Positive ADAM questionnaire was found 10(11.4%) healthy subjects. It was observed that 22.2% patients of CKD stage 3, 24.4% of CKD stage 4, 25.4% of CKD stage 5 and 27.8% of CKD stage 5D (Figure-1). It was observed that in group A (CKD patients), 60(66.7%) patients had normal (3.2-14.6 ng/ml) S. testosterone and their mean S. testosterone were found 4.29±1.9 ng/ml. In group B (Healthy subjects), all subjects had normal (3.2-14.6 ng/ml) S. testosterone and their mean S. testosterone were found 9.15±1.2 ng/ml. The mean S. testosterone difference was statistically significant (p<0.05) between two groups (Table III) . A line diagram showed progressive lowering of mean S. Testosterone from healthy to progression of CKD ( Figure 2 ). In this current study it was observed that positive response to ADAM questionnaire was found 11.4% in healthy subjects, 10.1% in CKD stage 3, 54.5% in CKD stage 4, 100% in CKD stage 5 and 5D. Among those groups only CKD stage 5 and 5D patients observed low S. testosterone and was found 39.1% and 84.0% respectively (Figure 3) . A strong negative Spearman's rank correlation (r=-0.893; p=0.001) existed between Stages of CKD and S. Testosterone of CKD patients (Figure 4 ). 
Discussion:
This cross-sectional study was carried out with an aim to evaluate the serum testosterone level in males and response to ADAM questionnaire with chronic kidney disease (CKD).
For this purpose, a total of 90 diagnosed cases of adult male with different stages of CKD (CKD stage 3, 4, 5 and 5D) patients along with age matched 88 healthy individuals were included as per inclusion and exclusion criteria.
In this present study it was observed that 90 patients having chronic kidney disease among them majority 37(41.1%) patients belonged to age 41-50 years. In this present study it was observed that 22.2% patients had CKD stage 3, 24.4% had stage 4, 25.4% had stage 5 and 27.8% had stage 5D. As many as 40 to 60% of CKD stage-5 men have been reported to be hypogonadal on the basis of low concentrations of total and free testosterone (Carrero 2011 In this current study it was observed that positive response to ADAM questionnaire was found 11.4% in healthy subjects, 10.1% in CKD stage 3, 54.5% in CKD stage 4, 100% in CKD stage 5 and 5D. Among those groups only CKD stage 5 and 5D patients observed low S. testosterone and was found 39.1% and 84.0% respectively.
In this present study a negative Spearman's rank correlation (r=-0.893; p=0.001) between Stage of CKD and S. Testosterone of CKD patients was observed. Similarly, (Zainab et al. 2014) reported that there was a significant negative correlation between free testosterone in both ESRD patients and control groups with a significant difference in testosterone between these two groups. (Colak et al. 2014) showed that CKD patients had more cardiovascular risk factors (CVRF) than transplant patients and also that their concomitant testosterone levels were low.
